Navigation Links
LJI develops new approach to identify genes poised to respond in asthma patients
Date:7/8/2014

SAN DIEGO July 8, 2014 In a study published yesterday in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 200 million people world wide.

An organism's genetic material, also known as its genome, can be divided into small sections or 'neighborhoods.' Scientists can determine which genetic neighborhoods in a cell are active, or primed for gene production, by looking for a marker on the genome called an enhancer. An enhancer can increase the production of genes in its immediate neighborhood. The goal of the published study is to find genes whose neighborhoods are active in diseased cells, but inactive in healthy cells. Genes that are in active neighborhoods in diseased cells are likely to contribute to disease, and can potentially be targeted with drug treatments.

In order to find genetic neighborhoods that are active in asthmatic disease, the scientists in Vijayanand's group focus their experiments on memory cells, which develop abnormally in asthma patients. Memory cells are responsible for quickly responding to foreign substances called antigens that the host has been exposed to previously. Air passage inflammation, which characterizes asthma, is mediated by an overactive response to inhaled antigens by memory cells.

By applying his technique in small populations of abnormal memory cells, Vijayanand highlights 33 genetic neighborhoods that are highly active in diseased cells, but inactive in healthy cells, shifting the focus of asthma research to specific genes that are located in these neighborhoods.

Genome-wide association studies (GWAS) that are less precise, have previously identified 1,500 potential target regions associated with asthmatic disease. According to Vijayanand, these targets are too numerous to study individually, and as a result, the field has remained focused on just a few molecules for discovery of new asthma treatments. Using their approach, Vijayanand's team searched the 1,500 targets for those that have the greatest likelihood of contributing to asthmatic disease. "Our unbiased and hypothesis-free approach has revealed a staggering but manageable number of new molecules that could play a role in asthma, and thus are potentially novel therapeutic targets," said Vijayanand.

Vijayanand and his team completed the study using different amounts of cells from the blood of healthy individuals and asthmatic patients. They did so in order to determine the smallest number of cells that were required for their technique, and found that it works with as little as 10,000 cells, which is significantly less than the millions of cells required to use other methods. Vijayanand envisions using this technique in situations where access to cells is limited, such as tumor biopsy for cancer.

The frequency of asthma is rising across the developed world as well as in several large developing countries. Treatment for asthma usually includes long-term nonspecific medication, as there is no cure at present.

Vijayanand says this study provides information that can be the starting point for many avenues of research and treatment. He says, "our study provides a rich and comprehensive resource that will be useful to the scientific community, enabling investigators to conduct their own detailed studies of the functional significance of the novel genes and enhancers that we have identified."


'/>"/>

Contact: Daniel Moyer
dmoyer@liai.org
858-752-6535
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Related medicine news :

1. KAIST develops TransWall, a transparent touchable display wall
2. Exploring how the nervous system develops
3. InventHelp Inventor Develops Physical-Therapy Equipment (LAX-452)
4. Inventor and InventHelp Client Develops Convenient Foot-Care Accessory (HLW-1194)
5. InventHelp Inventor Develops Infant Urine Collection Device (OCM-592)
6. InventHelp Inventor Develops Hemorrhoid Relief Kit (HTM-3000)
7. Inventors from InventHelp Develops Improved Hot/Cold Pack (AUP-327)
8. InventHelp Inventor Develops Blood-Pressure Testing Accessory (LAX-437)
9. Inventor and InventHelp Client Develops Inconspicuous Hearing Aids (FED-1269)
10. InventHelp Inventor Develops Improved Wheelchair (CBA-2287)
11. InventHelp Inventor Develops Alternative to Steps (BGF-683)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter what people call ... like never before. More than a map, new social marketplace Weedable goes ... – and for the first time – each other. A social marketplace like no ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from ... follow a protocol to quickly identify and treat the condition. , The mandate ... have saved Rory or anyone else’s life. , Now, five years after the ...
(Date:5/19/2017)... ... May 19, 2017 , ... DMG Productions is ... of Innovations with Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. ... clean, organic dietary supplement made from naturally occurring ingredients. Innovations will enlighten viewers ...
(Date:5/19/2017)... , ... May 19, 2017 , ... ... services and retirement planning assistance to families and business owners in the region, ... to advocate for MS sufferers and their families. , Multiple sclerosis (MS) is ...
(Date:5/19/2017)... ... May 18, 2017 , ... ML Billing, 2016 Billing Company of the ... specializes in large group practices, is pleased to announce their 30th anniversary. Not only ... the standard in all aspects of full-service medical billing. This has allowed ML Billing ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... 2017  George Clinical, a leading full-service CRO in ... Vector Oncology, a Memphis -based ... today that George Clinical has acquired Vector Oncology,s Pharma Services ... dual purpose of strengthening the ability of George ... solutions throughout the Asia-Pacific , ...
Breaking Medicine Technology: